FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to pharmaceuts. What is described is a pharmaceutical preparation containing 1-(3-cyclopropylmethoxy-4-difluoromethoxyphenyl)-2-(3,5-dichloro-1-oxypyridin-4-yl)ethyl ester (-)-3-cyclopropylmethoxy-4-methansulphonylaminobenzoic acid, surfactant, co-solvent and propellant. The surfactant is specified in polyethylene glycol 600 (PEG600) or polyvinylpyrrolidone (PVP), or a mixture thereof. The co-solvent represents ethanol. The propellant represents hydrofluoralkan specified in a group containing 1,1,1,2-tetrafluorethane (HFA134a), 1,1,1,2,3,3,3-heptafluor-n-propane (HFA227) and a mixture thereof.
EFFECT: invention provides implementing the above application.
6 cl, 7 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| 5-(2-{[6-(2,2-DIFLURO-2-PHENYLETHOXY)HEXYL]AMINO}-1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE HEMINAPADISYLATE AS β2 ADRENERGIC RECEPTOR AGONIST | 2008 |
|
RU2495029C2 |
| INHALATION COMPOSITION | 2003 |
|
RU2301673C2 |
| PHARMACEUTICAL AEROSOL FORMULATIONS OF FORMOTEROL AND BECLOMETASONE DIPROPIONATE | 2010 |
|
RU2650175C2 |
| COMBINATION TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 2010 |
|
RU2561052C2 |
| ORGANIC COMPOUNDS | 2001 |
|
RU2292890C2 |
| NEW DOSE AND FORMULATION | 2009 |
|
RU2608713C2 |
| PHARMACEUTICAL COMPOSITION | 2011 |
|
RU2642624C2 |
| COMBINATIONS CONTAINING ANTIMUSCARINE AGENTS AND CORTICOSTEROIDS | 2005 |
|
RU2385156C2 |
| COMPOSITIONS COMPRISING FORMOTEROL AND THIOTROPIUM SALT | 2000 |
|
RU2238085C2 |
| MEDICINAL AGENT AND PHARMACEUTICAL SET DESIGNATED FOR ASTHMA TREATMENT | 2000 |
|
RU2270670C2 |
